A Phase III Double-Blind, Parallel Group, Multicenter Study to Compare the Efficacy and Safety of Xlucane Versus Lucentis® in Patients With Neovascular Age-Related Macular Degeneration
Phase of Trial: Phase III
Latest Information Update: 12 Nov 2019
Price : $35 *
At a glance
- Drugs Ranibizumab (Primary)
- Indications Choroidal neovascularisation; Wet age-related macular degeneration
- Focus Registrational; Therapeutic Use
- Acronyms XPLORE
- Sponsors Xbrane
- 13 Jun 2019 Status changed from not yet recruiting to recruiting.
- 20 Mar 2019 New source identified and integrated (European Clinical Trials Database EudraCT2018-002930-19)
- 28 Feb 2019 According to a Xbrane media release, company shall pay half of the costs for the trial, which is estimated to approximately MSEK 300-350.